Trial
NCT04037891
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AKARI Therapeutics
Collaborators
—
Condition
Keratoconjunctivitis, Atopic
Intervention
rVA576
Why stopped
The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-10